Royalty Pharma Sub-Manager, LLC
Portfolio value QoQ: +40.0% 13F does not disclose cash
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 17.66% Est. buys $54,091,515 · sells $36,615,386
Performance vs S&P 500
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Sector breakdown
Full portfolio 4 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| CYTK | $83,519,594 | 34.52% | 980,392 | $18,901,957 | |||
| ZBIO | $60,611,247 | 25.05% | 2,388,150 | $13,922,914 | |||
| Unknown issuer (CUSIP: 482931102) | $54,091,515 | 22.36% | 2,455,357 | Up ×1 | |||
| BHVN | $43,695,224 | 18.06% | 2,936,507 | $18,852,375 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 482931102) | $54,091,515 | 2,455,357 | 22.36% |
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| BCRX | June 30, 2026 | 3,846,154 | $36,615,386 | -18.3% |